Moderna anticipates $18.4 billion APA coronavirus vaccine sales

26 February 2021

US biotech Moderna (Nasdaq: MRNA), which is pioneering messenger RNA (mRNA) therapeutics and vaccines, reported financial results for the fourth quarter and fiscal year 2020 and highlighted pipeline progress yesterday.

Moderna’s shares rose more than 8% to $157.12 in early trading on Thursday, but that was not a reaction to the figures, but rather the projection that the company expects to book $18.4 billion in Advanced Purchase Agreements (APAs) for its COVID-19 Vaccine Moderna in 2021.

This is an increase from previous guidance of $11.7 billion provided at a financial conference early this year (but not a surprise given previously reported government option exercises). It is also more than the $15 billion that Pfizer (NYSE: PFE) said it expected from its COVID-19 vaccine when it reported financial earlier this month.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK